Avandia - An Endocrinologist's Perspective

Medical Author: Ruchi Mathur, MD, FRCP(C)
Medical Editor: Melissa Conrad Stöppler, MD

Steven Nissan and colleagues released an article in the New England Journal of Medicine recently that reviewed the relationship between rosiglitazone (Avandia) and the risk of heart attack and death from cardiovascular causes. Rosiglitazone is one drug in a class of insulin sensitizers known as thiazolidinediones, or TZDs. This class of drugs is commonly prescribed for the treatment of type 2 diabetes and for insulin resistance. The authors of the recent paper reviewed 42 published and unpublished randomized clinical trials, studying patients taking rosiglitazone for a minimum of 24 weeks. Their analysis found a significantly increased risk for heart attack and an even higher risk for overall cardiovascular death from all causes.